Clinical Characteristics and Epidemiological Analysis of Pneumocystis Jirovecii Pneumonia Infection in Kidney Transplant Patients with Trimethoprim-Sulfamethoxazole Dose Reduction Prophylaxis Strategy
DOI: https://doi.org/10.2147/idr.s461206
2024-06-08
Infection and Drug Resistance
Abstract:Wenya Shan, 1– 3 Liangping Wang, 1, 4 Jiayi Qin, 1– 3 Wenhan Peng, 5 Kuifen Ma 1– 3 1 Department of Clinical Pharmacy, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, People's Republic of China; 2 Zhejiang Provincial Key Laboratory for Drug Evaluation and Clinical Research, Hangzhou, People's Republic of China; 3 Zhejiang Provincial Key Laboratory of Traditional Chinese Medicine for Clinical Evaluation and Translational Research, Hangzhou, People's Republic of China; 4 Department of Pharmacy, Hangzhou Linping District Hospital of Integrated Chinese and Western Medicine, Hangzhou, People's Republic of China; 5 Kidney Disease Center, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, People's Republic of China Correspondence: Wenhan Peng, Kidney Disease Center, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, People's Republic of China, Tel +8687233411, Email Kuifen Ma, Department of Clinical Pharmacy, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, People's Republic of China, Email Background: The administration of trimethoprim-sulfamethoxazole (TMP-SMX) for the prophylaxis of Pneumocystis jirovecii pneumonia (PJP) has proven to be highly efficacious in individuals who have undergone kidney transplantation. Nevertheless, the potential for severe adverse reactions associated with this treatment cannot be overlooked, and the determination of an optimal dosage regimen continues to be a matter of investigation. The current study evaluated the effectiveness of low-dose TMP-SMX for PJP prophylaxis in kidney transplant patients and conducted an analysis of the clinical characteristics and epidemiological trends in patients with PJP infection. Methods: This retrospective analysis studied electronic medical records of 1763 kidney transplant recipients from 2017 to 2020. These patients were initially prescribed a daily half-strength TMP-SMX (40 mg/200 mg), and the efficacy of this regimen was assessed during a follow-up period of 3– 51 months. Results: Under our PJP prevention and adjustment strategy, 24 patients were infected with PJP. The overall morbidity of PJP infection in our study was 1.36%, corroborates with findings from previously published studies. Among these 24 patients, up to 87.5% had their dosage adjusted due to increased creatinine or other adverse reactions, the most frequent dose was daily quarter-strength TMP-SMX (20 mg/100 mg). TMP-SMX prophylaxis successfully postponed and distributed the onset of PJP, with the mean duration from transplantation to the occurrence of PJP being 13.50± 7.11 months. Conclusion: Daily administration of half-strength TMP-SMX can effectively prevent PJP, and prolonging prophylaxis with this medication may potentially reduce the incidence of infection. Keywords: efficacy, kidney transplant recipients, Pneumocystis jirovecii pneumonia, trimethoprim-sulfamethoxazole Pneumocystis jirovecii pneumonia (PJP) is a serious, potentially fatal complication, with high incidence among HIV, cancer, or transplant recipients. Even with active antibiotic treatment, the mortality rate associated with PJP can increase to as high as 50%. 1,2 Before the adoption of routine prophylaxis, 5% to 15% of solid organ transplant patients were at risk of developing PJP following transplantation. 3,4 Prophylaxis of PJP with trimethoprim-sulfamethoxazole (TMP-SMX) has proven to be exceptionally effective in kidney transplant recipients (KTRs). 5 The recommended dosing for TMP-SMX spans from single-strength (80 mg/400 mg) daily to double-strength (160 mg/800 mg) thrice weekly, with the advised duration of PJP prophylaxis extending from six to twelve months. 6 TMP-SMX associates with numerous adverse drug reaction, such as leukopenia, absolute neutropenia, renal toxicity, thrombocytopenia, anemia, and hepatitis. These adverse events are often poorly tolerated and may lead to the discontinuation of treatment. For patients who cannot tolerate TMP-SMX, aerosolized pentamidine, dapsone, or atovaquone offer viable prophylactic alternatives for the prevention of PJP. However, it should be noted that access to these medications in China remains limited. TMP-SMX remains the preferred prophylactic agent for preventing PJP and is widely used in clinical settings. Thus, post-transplant management requires a balance between the prevention of PJP and the mitigation of adverse reactions associated with TMP-SMX. Studies have confirmed that six months of daily single-strength TMP-SMX prophylaxis was more efficacious than thrice weekly double-strength TMP-SMX. -Abstract Truncated-
pharmacology & pharmacy,infectious diseases